S
Sachin Khunti
Researcher at Queen Mary University of London
Publications - 4
Citations - 286
Sachin Khunti is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Type 2 diabetes & Context (language use). The author has an hindex of 4, co-authored 4 publications receiving 138 citations. Previous affiliations of Sachin Khunti include University of Portsmouth.
Papers
More filters
Journal ArticleDOI
Classification of aerosol-generating procedures: a rapid systematic review.
Tanya D Jackson,Danika Deibert,Graeme Wyatt,Quentin Durand-Moreau,Anil Adisesh,Kamlesh Khunti,Sachin Khunti,Simon Smith,Xin Hui S Chan,Lawrence Ross,Nia Roberts,Elaine Toomey,Trisha Greenhalgh,Isheeta Arora,Susannah M Black,Jonathan Drake,Nandana Syam,Robert J Temple,Sebastian Straube +18 more
TL;DR: There is sufficient evidence of agreement across different international guidelines to classify certain procedure groups as aerosol generating, however, some clinically relevant procedures received surprisingly little mention in the source documents.
Journal ArticleDOI
Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia.
TL;DR: The possible aetiologies, consequences and solutions of therapeutic inertia are discussed, drawing upon evidence from published literature on the subject of type 2 diabetes.
Journal ArticleDOI
Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review
TL;DR: An overview of clinical inertia in the management of type 2 diabetes, relating to the initiation of oral antidiabetic and insulin therapies, reasons for clinical inertia and strategies for overcoming clinical inertia are given.
Journal ArticleDOI
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
TL;DR: This review highlights the current concerns related to CO VID‐19 and provides advice in terms of the therapeutic uncertainty and potential adverse harms associated with therapy when managing people, particularly those with cardiometabolic diseases, who have contracted or are at increased risk of contracting COVID‐19.